Results 281 to 290 of about 188,637 (301)

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Cancer Immunology, Immunotherapy, 2007
Francois Ghiringhelli, Cedric Menard, Sylvain Ladoire   +2 more
exaly  

Tirofiban dosage regimen established

Inpharma Weekly, 1996
openaire   +1 more source

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Journal of Clinical Oncology, 2012
Josep Tabernero Caturla, Hans Prenen
exaly  

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

American Journal of Ophthalmology, 2009
Philip J Rosenfeld, Harry W Flynn
exaly  

Computerized dosage regimens for highly toxic drugs

American Journal of Health-System Pharmacy, 1974
F J, Goicoechea, R W, Jelliffe
openaire   +2 more sources

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Lancet, The, 2010
Joseph J Eron, Benjamin Young, Michael D Miller   +2 more
exaly  

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

American Journal of Ophthalmology, 2007
Philip J Rosenfeld, Harry W Flynn
exaly  

Dosage Regimen Design: A Pharmacokinetic Approach

The Journal of Clinical Pharmacology, 1992
openaire   +2 more sources

Discrepancies in Recommended Dosage Regimens of Drugs

The Journal of Clinical Pharmacology, 1976
openaire   +3 more sources

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Lancet, The, 2006
Sharon L Walmsley, Bonaventura Clotet, Adriano Lazzarin   +2 more
exaly